Acid ceramidase inhibition: a novel target for cancer therapy

X Liu; S Elojeimy; L S Turner; A E M Mahdy; Y H Zeidan; A Bielawska; J Bielawski; J Y Dong; A M El-Zawahry; G W Guo; Y A Hannun; D H Holman; S Rubinchik; Z Szulc; T E Keane; M Tavassoli; J S Norris

doi:10.2741/2843

Acid ceramidase inhibition: a novel target for cancer therapy

X Liu, S Elojeimy, L S Turner, A E M Mahdy, Y H Zeidan, A Bielawska, J Bielawski, J Y Dong, A M El-Zawahry, G W Guo, Y A Hannun, D H Holman, S Rubinchik, Z Szulc, T E Keane, M Tavassoli, J S Norris

Centre for Host Microbiome Interactions

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Abstract

During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid sphingosine-1- phosphate, has emerged as an important factor in cancer pathology and resistance to therapy. Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of ceramide and decreasing sphingosine-1-phosphate. Particularly, inhibition of the ceramide metabolizing enzyme acid ceramidase, whose overexpression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy. In this review, we consider our recent work with acid ceramidase inhibitors, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy

Original language	English
Pages (from-to)	2293 - 2298
Number of pages	6
Journal	Frontiers in Bioscience
Volume	13
Issue number	6
DOIs	https://doi.org/10.2741/2843
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2741/2843

Cite this

Liu, X., Elojeimy, S., Turner, L. S., Mahdy, A. E. M., Zeidan, Y. H., Bielawska, A., Bielawski, J., Dong, J. Y., El-Zawahry, A. M., Guo, G. W., Hannun, Y. A., Holman, D. H., Rubinchik, S., Szulc, Z., Keane, T. E., Tavassoli, M., & Norris, J. S. (2008). Acid ceramidase inhibition: a novel target for cancer therapy. Frontiers in Bioscience, 13(6), 2293 - 2298. https://doi.org/10.2741/2843

@article{125d7443c1b04d3fa63f2848174504d8,

title = "Acid ceramidase inhibition: a novel target for cancer therapy",

abstract = "During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid sphingosine-1- phosphate, has emerged as an important factor in cancer pathology and resistance to therapy. Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of ceramide and decreasing sphingosine-1-phosphate. Particularly, inhibition of the ceramide metabolizing enzyme acid ceramidase, whose overexpression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy. In this review, we consider our recent work with acid ceramidase inhibitors, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy",

author = "X Liu and S Elojeimy and Turner, {L S} and Mahdy, {A E M} and Zeidan, {Y H} and A Bielawska and J Bielawski and Dong, {J Y} and El-Zawahry, {A M} and Guo, {G W} and Hannun, {Y A} and Holman, {D H} and S Rubinchik and Z Szulc and Keane, {T E} and M Tavassoli and Norris, {J S}",

year = "2008",

doi = "10.2741/2843",

language = "English",

volume = "13",

pages = "2293 -- 2298",

journal = "Frontiers in Bioscience",

publisher = "Frontiers in Bioscience",

number = "6",

}

TY - JOUR

T1 - Acid ceramidase inhibition: a novel target for cancer therapy

AU - Liu, X

AU - Elojeimy, S

AU - Turner, L S

AU - Mahdy, A E M

AU - Zeidan, Y H

AU - Bielawska, A

AU - Bielawski, J

AU - Dong, J Y

AU - El-Zawahry, A M

AU - Guo, G W

AU - Hannun, Y A

AU - Holman, D H

AU - Rubinchik, S

AU - Szulc, Z

AU - Keane, T E

AU - Tavassoli, M

AU - Norris, J S

PY - 2008

Y1 - 2008

N2 - During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid sphingosine-1- phosphate, has emerged as an important factor in cancer pathology and resistance to therapy. Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of ceramide and decreasing sphingosine-1-phosphate. Particularly, inhibition of the ceramide metabolizing enzyme acid ceramidase, whose overexpression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy. In this review, we consider our recent work with acid ceramidase inhibitors, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy

AB - During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid sphingosine-1- phosphate, has emerged as an important factor in cancer pathology and resistance to therapy. Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of ceramide and decreasing sphingosine-1-phosphate. Particularly, inhibition of the ceramide metabolizing enzyme acid ceramidase, whose overexpression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy. In this review, we consider our recent work with acid ceramidase inhibitors, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy

U2 - 10.2741/2843

DO - 10.2741/2843

M3 - Article

VL - 13

SP - 2293

EP - 2298

JO - Frontiers in Bioscience

JF - Frontiers in Bioscience

IS - 6

ER -

Acid ceramidase inhibition: a novel target for cancer therapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this